Phase 3 Trial

A Phase 3 trial is the large-scale, confirmatory stage of drug development — the “pivotal” study (or studies) that a New Drug Application or Biologics License Application relies on to demonstrate a drug’s benefit-risk profile is favorable enough to approve. Under 21 CFR 312.21(c), Phase 3 studies “are expanded controlled and uncontrolled trials… performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.” Where Phase 2 looks for an efficacy signal in a few hundred patients, Phase 3 is sized and controlled to confirm it. See CASRAI’s Clinical Trial Phases guide for the full sequence.

Why Phase 3 studies are called “pivotal”

FDA generally expects “substantial evidence” of effectiveness to rest on results from more than one adequate and well-controlled investigation — in practice, most NDA/BLA submissions rely on two positive pivotal Phase 3 trials, though a single sufficiently robust and internally replicated trial can occasionally suffice. A pivotal trial is prospectively designed around one or more pre-specified primary endpoints, powered to detect a clinically meaningful treatment effect with adequate statistical confidence, and run under a protocol locked well before unblinding — distinguishing it from the more exploratory endpoint-hunting typical of Phase 2.

Size, duration, and control design

FDA’s patient-facing guidance puts typical Phase 3 enrollment at 300 to 3,000 participants (21 CFR 312.21(c) states “several hundred to several thousand subjects”), running one to four years depending on the endpoint and disease. Because Phase 3 studies are larger, longer, and often multi-site or multi-region, they’re more likely than earlier phases to surface less common adverse reactions and to generate the long-term safety data that feeds directly into product labeling. Control design typically follows one of three templates: placebo-controlled (where withholding treatment is ethical), active-comparator superiority, or active-comparator non-inferiority — the choice depends heavily on whether an established effective therapy already exists for the indication.

What Phase 3 doesn’t guarantee

A positive Phase 3 result is necessary but not sufficient for approval: FDA still reviews the full benefit-risk relationship, manufacturing and labeling adequacy, and can require additional studies. Historically only about 25-30% of drugs that enter Phase 3 go on to approval, reflecting that some pivotal trials fail to replicate a Phase 2 signal, show an unacceptable safety trade-off at scale, or fail on a pre-specified secondary or safety endpoint even after meeting the primary one.

Administrative and regulatory context

Phase 3 trials remain filed under the originating IND, with the same 21 CFR 312.32 expedited safety-reporting obligations, and their results form the clinical core of the marketing application filed under 21 CFR Part 314. See CASRAI’s Clinical Trial Phases guide for how Phase 3 fits alongside Phase 0, Phase 1, Phase 2, and Phase 4.